Evaheart Revenue and Competitors
Estimated Revenue & Valuation
- Evaheart's estimated annual revenue is currently $3.1M per year.
- Evaheart's estimated revenue per employee is $155,000
Employee Data
- Evaheart has 20 Employees.
- Evaheart grew their employee count by 18% last year.
Evaheart's People
Name | Title | Email/Phone |
---|---|---|
1 | Clinical Support Specialist | Reveal Email/Phone |
2 | Lead Clinical Support Specialist | Reveal Email/Phone |
3 | Associate Clinical Trial Lead | Reveal Email/Phone |
4 | Clinical Support Specialist | Reveal Email/Phone |
5 | XR Program Lead | Reveal Email/Phone |
6 | Clinical Support Specialist | Reveal Email/Phone |
Evaheart Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2.5M | 16 | 45% | N/A | N/A |
#2 | $13.8M | 89 | -7% | N/A | N/A |
#3 | $18.6M | 120 | 3% | $1.8M | N/A |
#4 | $0.9M | 6 | -40% | N/A | N/A |
#5 | $4.2M | 27 | 0% | N/A | N/A |
#6 | $3.4M | 22 | 47% | N/A | N/A |
#7 | $9.6M | 62 | 29% | N/A | N/A |
#8 | $0.9M | 6 | 20% | N/A | N/A |
#9 | $1.7M | 11 | 10% | N/A | N/A |
#10 | $15.2M | 98 | -8% | N/A | N/A |
What Is Evaheart?
LEADING LVAD COMPANY IN THE STATE OF TEXAS Evaheart, Inc. ("EVI") is a medical device company based in the Texas Medical Center of Houston. EVI was established to gain regulatory approval and commercialize the EVAHEART®2 Left Ventricular Assist System in the North American market and start distribution in Europe. Under an FDA-approved IDE, a Multi-Center Prospective Randomized Clinical Trial (COMPETENCE TRIAL) of the EVAHEART®2 LVAS is currently ongoing in US. OUR MISSION To return severe heart failure patients to their home with high quality of life. WHAT WE'VE ACHIEVED - Over 9-year durability testing with no mechanical failure. - Regulatory clearance granted (by PMDA) and now clinically used in Japan - Total 183 EVAHEART® LVAS have been implanted to-date (July-2018). - IDE (Investigational Device Exemption) approved by the FDA. - IDE clinical trial (BTT trial) in North America is underway. - New miniaturized pump and inflow cannula are implemented. "RESPECT PULSATILITY" (c) Christian Schmidt-Mewes
keywords:N/AN/A
Total Funding
20
Number of Employees
$3.1M
Revenue (est)
18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Evaheart News
Abbott Laboratories; LivaNova; Nipro Corporation; Terumo Corporation; Medtronic; BiVACOR; Evaheart; Abiomed. DOWNLOAD FREE SAMPLE REPORT:...
CorWave; SynCardia Systems; BiVACOR; Evaheart; Abiomed; Procyrion; NuPulseCV; Windmill Cardiovascular Systems. The study examines the following...
Evaheart; ReliantHeart; Sun Medical Technology Research; Sunshine Heart. Market segment by product type: BTT Therapy; BTD Therapy; Destination...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.9M | 20 | -23% | N/A |
#2 | $2.5M | 20 | -9% | $750M |
#3 | $2M | 20 | N/A | N/A |
#4 | $3.6M | 20 | 0% | N/A |
#5 | $1.6M | 20 | 18% | $23.5M |